Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...
After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation. The Clinical Frailty Scale (CFS) ...
Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...
During a live event, Andrew H. Lipsky, MD, and participants discuss emerging trial data and real-world applications of innovative CLL treatment combinations. As combination strategies continue to ...
Fixed-duration therapy achieved deeper remissions, with undetectable MRD in 73.3% of patients treated with venetoclax-obinutuzumab and 47.2% of those treated with venetoclax-ibrutinib. For patients ...
Richter transformation with CNS involvement in CLL patients results in poor prognosis and limited survival, with a median overall survival of 13 months. Treatment strategies for RT-CNS are often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results